{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:47:29Z","timestamp":1768722449355,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Aventis Pharmaceuticals Inc., Bridgewater, NJ"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Describe the efficacy of weekly docetaxel in various solid tumors, particularly in comparison with docetaxel administered every 3 weeks. List the common treatment-related toxicities of weekly docetaxel. Effectively manage the common toxicities related to weekly docetaxel.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Docetaxel (Taxotere\u00ae; Aventis Pharmaceuticals Inc.; Bridgewater, NJ) is a highly effective chemotherapeutic agent with proven efficacy in a number of solid tumors. However, myelosuppression can be a substantial concern when docetaxel is administered every 3 weeks. Myelosuppression can be particularly problematic in older patients and those being treated with palliative intent. Weekly dosing of docetaxel has been investigated in an effort to reduce toxicity and has been identified as a safe and effective regimen in clinical trials. Weekly docetaxel is generally administered at doses ranging from 30\u201340 mg\/m2\/week for 6 of 8 weeks or for 3 of 4 weeks. With weekly dosing, though efficacy is comparable, myelosuppression is substantially less, and the overall tolerability profile is better than with every-3-week dosing. Fatigue is a common toxicity associated with weekly docetaxel; other adverse effects that are seen in a minority of patients include hyperlacrimation, nail toxicity, and alopecia. These side effects are dose related and can generally be managed through dose reductions or alterations in the weekly schedule. Because of the favorable tolerability profile, weekly docetaxel is under investigation in combination with other chemotherapeutic agents and with novel targeted agents in a variety of tumor types. The results of these ongoing studies will further define the place of weekly docetaxel in cancer therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-5-538","type":"journal-article","created":{"date-parts":[[2004,10,11]],"date-time":"2004-10-11T22:42:42Z","timestamp":1097534562000},"page":"538-545","source":"Crossref","is-referenced-by-count":42,"title":["Practical Aspects of Weekly Docetaxel Administration Schedules"],"prefix":"10.1093","volume":"9","author":[{"given":"John D.","family":"Hainsworth","sequence":"first","affiliation":[{"name":"The Sarah Cannon Cancer Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"2021122209454669500_R1","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122209454669500_R2","first-page":"43a","article-title":"TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up","volume":"82","author":"Martin","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209454669500_R3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122209454669500_R5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate","volume":"28","author":"Berry","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454669500_R6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"2021122209454669500_R7","first-page":"14","article-title":"Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results","volume":"26","author":"Picus","year":"1999","journal-title":"Semin Oncol"},{"issue":"suppl 17","key":"2021122209454669500_R8","first-page":"19","article-title":"A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2","volume":"26","author":"Friedland","year":"1999","journal-title":"Semin Oncol"},{"key":"2021122209454669500_R9","first-page":"52a","article-title":"Preliminary results of a phase II randomized trial of docetaxel (taxotere) as a single agent chemotherapy (CT) administered weekly or 3-weekly in patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Climent","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R10","first-page":"50b","article-title":"Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study","volume":"21","author":"Sedky","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R11","first-page":"625","article-title":"Second-line docetaxel administered every 3 weeks versus weekly in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial","volume":"22","author":"Camps","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R12","first-page":"625","article-title":"Effect on quality-of-life (QoL) of weekly vs 3-weekly docetaxel (D) in second-line treatment of advanced non-small-cell lung cancer: the DISTAL randomized phase 3 study","volume":"22","author":"Gridelli","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.1994.12.7.1458","article-title":"Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis","volume":"12","author":"Tomiak","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R14","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008399712913","article-title":"Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration","volume":"10","author":"Briasoulis","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122209454669500_R16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s002800000184","article-title":"A dose escalation study of weekly docetaxel in patients with advanced solid tumors","volume":"46","author":"Kouroussis","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122209454669500_R17","first-page":"58a","article-title":"Weekly docetaxel with or without corticosteroid premedication as first or second-line treatment in patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Stemmler","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R18","first-page":"108a","article-title":"Phase-II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC)","volume":"19","author":"Jackisch","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R19","first-page":"125","article-title":"Dose-dense weekly docetaxel (Taxotere\u00ae) in metastatic breast cancer","volume":"57","author":"Loeffler","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209454669500_R20","first-page":"56b","article-title":"Phase II trial of weekly docetaxel (D) in heavily pretreated advanced breast cancer (ABC) patients","volume":"20","author":"Comandone","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdf027","article-title":"Phase II study of weekly docetaxel in patients with metastatic breast cancer","volume":"13","author":"Aihara","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122209454669500_R22","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial","volume":"19","author":"Hainsworth","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1012557528952","article-title":"Weekly docetaxel (Taxotere) in patients with metastatic breast cancer","volume":"12","author":"Stemmler","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122209454669500_R24","first-page":"115a","article-title":"Weekly docetaxel (D) for metastatic breast cancer (MBC) progressing after anthracycline treatment","volume":"19","author":"Ramos","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R25","first-page":"126","article-title":"Weekly docetaxel in pretreated patients with metastatic breast cancer","volume":"57","author":"Rittershaus","year":"1999","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"2021122209454669500_R26","first-page":"1","article-title":"Weekly taxanes in treatment of metastatic breast cancer","volume":"18","author":"L\u00fcck","year":"2000","journal-title":"Cancer Invest"},{"key":"2021122209454669500_R27","first-page":"127","article-title":"Weekly docetaxel for metastatic breast cancer (MBC): a phase II trial","volume":"57","author":"Fornasiero","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209454669500_R28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R29","first-page":"119a","article-title":"Weekly chemotherapy schedule in advanced breast cancer (ABC) patients: ten-year experience at the Regina Elena Cancer Institute","volume":"19","author":"Nistico","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R30","first-page":"119a","article-title":"Weekly docetaxel in patients with advanced malignancies: toxicity profile and activity results","volume":"18","author":"Climent","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000070285","article-title":"Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy","volume":"64","author":"Petrioli","year":"2003","journal-title":"Oncology"},{"issue":"suppl 15","key":"2021122209454669500_R32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0093-7754(01)90153-8","article-title":"Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report","volume":"28","author":"Oh","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454669500_R33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial","volume":"89","author":"Hainsworth","year":"2000","journal-title":"Cancer"},{"key":"2021122209454669500_R34","first-page":"272b","article-title":"Second-line therapy with weekly docetaxel in resistant or relapsed non-small cell lung cancer (NSCLC): final results","volume":"20","author":"Serke","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R35","first-page":"537a","article-title":"Early phase II of docetaxel in second line of advanced non small cell lung cancer (NSCLC): preliminary results","volume":"19","author":"Garcia-Lopez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 4","key":"2021122209454669500_R36","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0169-5002(01)00402-0","article-title":"Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study","volume":"34","author":"Valerio","year":"2001","journal-title":"Lung Cancer"},{"key":"2021122209454669500_R37","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2","article-title":"Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma","volume":"92","author":"Lilenbaum","year":"2001","journal-title":"Cancer"},{"key":"2021122209454669500_R38","first-page":"267b","article-title":"A phase II study of weekly docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC)","volume":"20","author":"Gomez","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(02)00306-9","article-title":"Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens","volume":"39","author":"Petrioli","year":"2003","journal-title":"Lung Cancer"},{"key":"2021122209454669500_R40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209454669500_R41","first-page":"745","article-title":"Weekly docetaxel in the elderly: outcomes in mean with androgen independent prostate cancer (AIPC) \u226570 vs &lt;70 years of age","volume":"22","author":"Berry","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454669500_R42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdf036","article-title":"Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect","volume":"13","author":"Esmaeli","year":"2002","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-5-538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-5-538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/5\/538\/41844391\/oncolo_9_5_538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/5\/538\/41844391\/oncolo_9_5_538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:23:10Z","timestamp":1640193790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/5\/538\/6387971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,9,1]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-5-538","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,9,1]]},"published":{"date-parts":[[2004,9,1]]}}}